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Abstract  27 
Background: Quantification of proteinuria with urinary protein-to-creatinine (UPC) ratio is part of 28 
the diagnostic process in feline patients suspected of chronic kidney disease (CKD). In affected 29 
cats, monitoring and substaging of UPC according to International Renal Interest Society (IRIS) 30 
guidelines is also necessary for the appropriate patients’ management. No information is available 31 
about the possible effect of analytical variability on urinary protein (UP) and UPC ratio in cats. 32 
Objectives: The aim of this study was to determine whether imprecision and method-dependent 33 
difference due to the two dye-binding methods pyrogallol red-molybdate (PRM) and coomassie 34 
brilliant blue (CBB) could affect substaging according to IRIS guidelines. 35 
Methods: Urine samples were collected from proteinuric and non-proteinuric cats. Intra-assay and 36 
inter-assay repeatability were assessed with both PRM and CBB. Urinary supernatants (n=120) 37 
were tested with both methods. Agreement between methods and concordance in samples 38 
classification according to IRIS guidelines were determined. 39 
Results: On average, PRM yielded higher CV (UP: 8.4±5.2%; UPC: 9.5±4.8%) than CBB (UP: 40 
5.6±2.6%; UPC: 7.2±2.6%) but similar rate of misclassifications were found in samples with UPC 41 
close to the IRIS cutoff. Although the two methods were correlated, CBB tended to yield UP and 42 
UPC values significantly higher (P<0.0001) than PRM. Constant and proportional errors between 43 
PRM and CBB were also found by the Passing Bablok test. Concordance in substaging samples 44 
according to IRIS was good (k coefficient =0.62). 45 
Conclusion: The two methods were precise but the higher UPC obtained with CBB may affect 46 
interpretation of the IRIS guidelines and clinical decisions.  47 
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 52 
Introduction 53 
Chronic kidney disease (CKD) is the most common renal disease in cats and is defined as structural 54 
and/or functional impairment of one or both kidneys that has been present for more than 3 months.1 55 
CKD may result from heterogeneous causes, often not identified but that can induce a progressive 56 
and irreversible damage to the kidneys.2 57 
Proteinuria is a sign of kidney damage, but also a strong indicator for progression of CKD.3-5 It was 58 
hypothesized that proteinuria accelerates progression of CKD by direct toxic effect of reabsorbed 59 
proteins on tubular epithelial cells;6 this chronic injury induces the release of cytokines, cellular 60 
apoptosis and tubular degeneration and atrophy, that, in turn, leads to interstitial inflammation and 61 
fibrosis.7,8 Proteinuria in cats with naturally occurring CKD is generally mild, with 90% and 49% of 62 
cats with CKD having a UPC of <1.0 and <0.25, respectively.9 The severity of proteinuria, 63 
however, has prognostic significance in terms of survival time.9,10 Consequently, the ACVIM 64 
consensus statement on the treatment of proteinuria recommends therapeutic intervention when 65 
UPC ≥0.4 in cats with CKD causing azotaemia.3 66 
Proteinuria can be routinely assessed via semi-quantitative methods, such as urine dipstick 67 
colorimetric test. However, false-positive reactions for proteins in healthy cats as well as in cats 68 
with CKD limit its utility.4,11,12 A large amount of cauxin (a 70kDa glycoprotein) has been 69 
demonstrated in feline urine and it is responsible for false positive protein results on urine dipstick 70 
tests.13 Therefore the single best test for the detection of proteinuria in cats is the UPC ratio.14 71 
The International Interest Renal Society (IRIS) proposed sub-staging of feline CKD based on UPC 72 
ratio and defined non-proteinuric (NP) patients with UPC ratio ≤ 0.20, borderline proteinuric (BP) 73 
patients with UPC ratio from 0.21 to 0.40 and proteinuric (P) patients with UPC ratio >0.40.15 74 
Although the gold standard for detection of proteinuria is the quantification of protein in a 24 hours 75 
urine collection, in feline medicine this approach is impractical in clinical settings. Currently, the 76 
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quantification of proteinuria with the urinary protein-to-creatinine (UPC) ratio in spot urine sample 77 
is considered a reliable estimation of the daily protein excretion in cats.16,17 78 
Although proteinuria in cats is routinely assessed as part of the diagnostic process in patients 79 
suspected of CKD,1,3,15 to the authors’ knowledge there is no information available about analytical 80 
factors that may affect the measurement of proteinuria. Dye-binding methods are easy to use, 81 
relatively rapid and inexpensive and there are several assays available to quantify the urinary 82 
proteins. Among these, Pyrogallol red-molybdate (PRM)18,19 and Coomassie brilliant blue (CBB)17 83 
are the most used.20,21 In human medicine it was shown that different methods for urinary protein 84 
quantification yielded discordant results22,23 and efforts were made to improve agreement.24,25 85 
Similarly, in dogs, the UPC ratio can be affected by different assays principles and as a 86 
consequence dogs with kidney diseases can be incorrectly sub-staged applying the IRIS guidelines. 87 
A recent study in dogs showed biases between CBB and PRM in quantification of urinary protein in 88 
canine urine and the latter tended to underestimate protein concentration.26 Moreover, also in cats 89 
there are reports demonstrating disagreements between analytical methods different to PRM and 90 
CBB.27,28 Other factors, such as different pre-analytical procedure in different laboratories, storage 91 
or pre-dilution have been shown to influence the quantification of urinary protein in dogs.29,30 On 92 
this regard, it’s important to highlight that the IRIS guidelines do not specify which method should 93 
be used to assess the thresholds proposed in sub-staging feline and canine patients with chronic 94 
kidney disease.  95 
No information on the analytical variability of the quantification of urinary protein in cats is 96 
available. Therefore, the aims of this study were to determine whether analytic factors affect the 97 
evaluation of the UPC ratio in cats. Specifically, the intra-assay and inter-assay repeatability of 98 
UPC ratio measurement were evaluated. In addition, agreement between two dye-binding methods 99 
(PRM and CBB methods) for measurement of total protein in feline urine was determined.  100 
 101 
Materials and Methods 102 
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Animals and sample collection 103 
One hundred seventy-four urine samples were prospectively collected from client-owned cats 104 
presented for routine diagnostic investigations  105 
Samples were collected from January 2015 to February 2016 at the Veterinary Teaching Hospital 106 
(University of Milan) and at a private clinical practice (Veterinary Hospital “Città di Pavia”) during 107 
routine health screen, under informed consent signed by the owners. According to the ethical 108 
committee statements of the University of Milan (number 2/2016), biological samples collected in 109 
this setting could be used also for research purposes. 110 
Due to the analytical nature of this study, cats were enrolled irrespective of age, sex and breed or 111 
underlining disease and also cats with diseases that could affect urine composition (e.g. CKD, lower 112 
urinary tract inflammation, neoplasia, etc.) were included.  113 
Eight to 10 mL of urine were collected from each cat by ultrasonographically-guided cystocentesis. 114 
Samples were sent within the syringe to the respective internal clinical pathology laboratories 115 
(labeled as “Lab 1” for university of Milan and “Lab 2” for Ospedale Veterinario “Città di Pavia”). 116 
 117 
Urinalysis 118 
Five millilitres of urine were transferred from the syringe to a sterile conical tube and were 119 
macroscopically evaluated for physical properties (color and turbidity) and assayed with dipstick 120 
for a semi-quantitative chemical analysis (Combur 10 test, Roche diagnostics, Risch-Rotkreuz, 121 
Switzerland). Urine specific gravity (USG) was determined by a handheld refractometer calibrated 122 
daily with distilled water (Clinical Refractometer, model 105, Sper Scientific, Scottsdale, AZ, 123 
USA).  124 
In order to perform sediment evaluation and supernatant collection, tubes were centrifuged at 450G 125 
for 5 minutes (Hermle Z300, Labnet international, Edison, NJ, USA). Then, 4.75 mL of supernatant 126 
was removed and transferred in other tubes for subsequent diagnostic biochemical analysis and for 127 
study purposes (see below). Supernatants were removed by suction using a dispensable pipette 128 
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according to current guidelines31 in order to avoid loss of sediment and supernatant contamination 129 
by elements of the sediment. Sediments were resuspended in the remaining 0,25 mL supernatant 130 
and slide preparation and microscopic interpretation were performed according to a previous 131 
study.31 Supernatants enrolled in “Lab 1” were used fresh for the analytical procedures described 132 
below. Supernatants collected at “Lab 2” were aliquoted (approximately 2 mL each sample) and 133 
stored at −20° within 2 hours from collection. Then, aliquots were shipped in batch under controlled 134 
temperature to “Lab 1” for inclusion in method comparison study (see below). 135 
 136 
 137 
Analytical methods 138 
Two commercially available colorimetric test kits were used for protein quantification on urine 139 
supernatants in “Lab 1”, one based on PRM (Urine proteins, Sentinel diagnostics, Milan, Italy) and 140 
the other based on CBB (Total protein Coomassie urine, Far Diagnostics, Pescantina (VR), Italy). 141 
The concentration of urinary protein was expressed in mg/dL either for PRM (UPPRM) or for CBB 142 
(UPCBB). Both methods were performed according to manufacturer’s instructions and were 143 
calibrated with the standards provided by the manufacturers. Specifically, PRM standard was stated 144 
to be “urinary protein” with no specification of the particular nature of the protein content whereas 145 
CBB standard was bovine serum albumin. The protein concentration of the PRM standards 146 
provided with the different lots used during the study period ranged from 109 to 122 mg/dL 147 
whereas the concentration of CBB standards was 100 mg/dL in all the lots used.  148 
Preliminary assays run in our lab demonstrated that PRM method was linear up to 210 mg/dL as 149 
reported by the manufacturer whereas CBB method, independently on the limit of linearity 150 
indicated by the producer (400 mg/dL), lose linearity at concentration higher than 120 mg/dL. 151 
Therefore, when CBB yielded values higher than 120 mg/dL, supernatants were diluted 1:5 with 152 
distilled water; then, samples were re-run with both PRM and CBB and the actual values were 153 
calculated based on the dilution factor. 154 
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Urinary creatinine concentration (UC) was measured with the modified Jaffe method (Creatinina, 155 
Real-Time Diagnostics, Viterbo, Italy) and was expressed as mg/dL. Linearity of the method is up 156 
to 30 mg/dL. 157 
When CBB method was applied in a working session, PRM and Jaffe methods were run first, due to 158 
the peculiarity of CBB reagent to stain the reagent needle of the automated analyser and the 159 
theoretical possibility of contamination and interference of Coomassie dye in the subsequent 160 
reaction.  161 
Because urinary creatinine concentration frequently exceeds the range of linearity of the method, 162 
supernatants were diluted 1:20 with distilled water in order to measure urinary creatinine and then 163 
the actual values were calculated. 164 
Except when differently specified, biochemical tests were performed in triplicate and the mean 165 
values were used for data analysis. 166 
All tests were performed with an automated biochemical analyser in Lab1 (Cobas Mira, Roche 167 
Diagnostics, Basel, Switzerland) and all methods were daily controlled with QC material (UriChem 168 
Level 1 and Level 2, Instrumentation Laboratory, Munich, Germany). Calibration was performed 169 
when the Westgard rule 12s was violated on control solutions. 170 
UPC ratios obtained with PRM (UPCPRM) and, UPC ratios obtained with CBB (UPCCBB) were 171 
calculated for each method. 172 
 173 
 174 
Intra-assay and inter-assay repeatability—The intra-assay imprecision was assessed on twenty 175 
fresh urine supernatants, testing samples 20 consecutive times in the same run for protein 176 
concentration (with both PRM and CBB methods) and for creatinine concentration; and the UPC 177 
ratio was calculated. Mean, SD and CV (calculated as CV = SD/mean X 100) for UPPRM, UPCBB, 178 
UC and thus UPC ratio for each method were calculated first on the whole set of samples and then 179 
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considering separately the results from samples with active (n = 11 samples) and inactive sediment 180 
(n = 9 samples). 181 
The inter-assay imprecision was assessed in 15 samples, immediately aliquoted after sampling and 182 
stored at -20°C. Each sample was measured on 5 consecutive working days. Urine proteins were 183 
measured with both methods (PRM and CBB), urine creatinine was also measured to calculate the 184 
UPC ratio with each method. Mean, SD and CV were calculated for UPPRM, UPCBB, UC and thus 185 
UPC ratio for each method. 186 
 187 
Effect of storage—Since frozen supernatant were used in the method comparison study, a 188 
preliminary evaluation of stability at -20°C were performed. To this aim, 25 fresh urinary 189 
supernatants were tested immediately after collection (T0) and after 4 weeks of storage at -20°C 190 
(300 µL stored aliquots) with UPPRM and UC after gently thawing and proper mixing before the 191 
analysis. This analysis was repeated with further 25 samples testing stability of UP and UPC 192 
measured with CBB. 193 
 194 
Method comparison study—Forty samples from “Lab1” and 80 samples from “Lab2” were 195 
included. Supernatants sent to “Lab1” were analysed fresh within 3 hours from collection, while 196 
supernatants from “Lab2” have been stored no longer than 4 weeks at -20°C before the assay. 197 
Urine protein concentration was measured using both PRM and CBB methods, creatinine 198 
concentration was measured to allow the calculation of UPC ratios for each method.  199 
UPC ratios obtained with both methods (PRM and CBB) were used to classify the patients as non-200 
proteinuric (NP), borderline proteinuric (BP) or proteinuric (P) according to the IRIS staging 201 
system. 202 
 203 
Statistical Analysis 204 
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A commercially available software (MedCalc® Statistical Software, version 16.8.4, Ostend, 205 
Belgium) was used. A P value <0.05 was considered statistically significant. Distribution of 206 
variables was assessed by Kolmogorov-Smirnov test. 207 
The possible correlation between intra-assay CV of urinary protein concentration, urinary creatinine 208 
concentration or UPC ratio, and the actual values of each of these variables, was investigated with 209 
Spearman correlation test. Mann-Whitney U test was applied to investigate difference in UP, UC 210 
and UPC ratios between samples with active and inactive sediment.  211 
For the evaluation focused on the influence of different storage conditions on UP, UC and UPC 212 
ratios, results obtained at T0 and 1 month later with both PRM and CBB were compared using a 213 
Wilcoxon signed rank test. 214 
For the method comparison study, the UP values obtained with PRM and CBB were compared to 215 
each other with Wilcoxon signed rank test to assess difference and assayed for correlation with the 216 
Spearman test. The same analysis has been run to compare the UPC ratios calculated using the 217 
PRM and the CBB method. The agreement between the two methods was assessed by Passing-218 
Bablok and Bland–Altman tests. 219 
The concordance of the two methods in classifying samples according to IRIS staging of proteinuria 220 
was assayed with the Cohen’s kappa (k) concordance test. The Cohen’s k coefficient was used to 221 
define concordance as “very good” (k = 0.8–1), “good” (k = 0.6–0.8), moderate (k = 0.4–0.6), “fair” 222 
(k = 0.2–0.4), “poor” (k = 0.0–0.2) or “absent” (k <0).32 Method comparison study tests were 223 
performed for the whole set of data and for the sub-sets of samples grouped according to the 224 
presence or absence of active sediment  225 
 226 
Results 227 
Intra-Assay and inter-assay variability 228 
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Descriptive statistics of the samples included in intra-assay and inter-assay evaluation and the 229 
respective CVs with regard of UPPRM, UPCBB, UC, UPCPRM and UPCCBB are shown in Table 1. Test 230 
for normality revealed a non-Gaussian distribution for both UP, UC and thus for UPC. 231 
The CV was lower for the UC than for UP (and UPC ratio) measured with both PRM and CBB. 232 
CBB method appeared more precise than the PRM method. The effect of this variability on sub-233 
staging of sample according to IRIS guidelines was assessed on 4 urine samples that had UPC ratios 234 
close to the threshold values (i.e. 0.2 and 0.4) and is shown in Table 2. 235 
No significant differences were found between mean values of UPPRM, UPCBB, UC, UPCPRM and 236 
UPCCBB between samples with active and inactive sediment. 237 
No significant correlations were found comparing intra-assay CV and mean values of UPPRM (r = –238 
0.08; P = 0.72), UPCBB (r = –0.29; P = 0.220), UC (r = –0.01; P = 0.95), UPCPRM (r = –0.23; P = 239 
0.33) and UPCCBB (r = –0.19; P = 0.42).  240 
 241 
Storage 242 
Compared to T0, UPPRM (median, range: 37.6 mg/dL, 9.2-508.7 mg/dL), UPCBB (median, range: 243 
54.7 mg/dL, 22.5-466.0 mg/dL), UPCPRM (median, range: 0.17, 0.06-6.18) and UPCCBB (median, 244 
range: 0.43, 0.06-5.82) did not statistically change after 1 month whereas UC (median, range: 245 
186.7, 64.1-394.7 mg/dL) was significantly higher (P = 0.016). 246 
 247 
Method comparison study 248 
Data referred to the whole caseload or to samples with inactive or active sediment are reported in 249 
Table 3. 250 
Forty-one (38.7%) urinary samples had an active sediment, while 65 (61.3%) had an inactive 251 
sediment. The most common sediment alteration was hematuria (68.3%), followed by leukocyturia 252 
(24.4%) and hematuria and leukocyturia (7.3%). 253 
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Using PRM, 66, 17 and 37 samples were classified as N, BP and P, respectively, whereas using 254 
CBB were 45, 25 and 50, respectively. 255 
CBB yielded constantly higher UP and UPC ratios compared to PRM and the difference was 256 
significant (P <0.0001) in all sets of samples.  257 
Urinary protein (PRM: P = 0.0146, CBB: P = 0.0104) and UPC ratio (PRM: P = 0.0035, CBB: P = 258 
0.0087) were significantly different between samples with active and inactive sediment. 259 
Correlations between UPPRM and UPCBB, and between UPCPRM and UPCPRM were highly significant 260 
(P <0.0001) in all groups of samples. In the whole set of samples correlation coefficients were 0.82 261 
and 0.91 for urinary proteins and for UPC, respectively; coefficients in the samples with active 262 
sediments were 0.96 for both proteinuria and UPC; in the samples with inactive sediments 263 
coefficients were 0.78 and 0.96 for protein and for UPC, respectively.  264 
Statistical results of the method comparison study (including intercept and slope with 95% 265 
confidence intervals) obtained by Passing-Bablok regression analysis (Figure 1 and Figure 2), and 266 
Bland-Altman biases with 95% limits of agreement obtained from UP and UPC ratio in the whole 267 
set of sample, in samples with active and with inactive sediments (Figure 3 and Figure 4) were 268 
shown in Table 4. Constant and proportional errors were found in all sets of samples, with the 269 
exception of UPC in inactive sediment set that yielded no constant bias. 270 
The agreement in staging samples according to IRIS guidelines (Table 4) was defined as “good” in 271 
the whole set of samples (k coefficient =0.62), “moderate” for both active and inactive groups of 272 
samples (0.59 and 0.56 respectively). 273 
 274 
Discussion  275 
In this study, analytical variability in quantification of feline urinary proteins and UPC ratio were 276 
evaluated in order to determine their potential effect on clinical decisions. Although from a practical 277 
point of view only samples with inactive sediment should be used for UPC interpretation, also 278 
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samples with active sediment were included in order to highlight the possible analytical difference 279 
between the two types of samples.  280 
The two methods for urinary protein quantification yielded CV values similarly to what already 281 
found in dogs.29 A higher value was found with PRM for the sample with protein concentration 282 
close to the lower limit of the range of linearity (20 mg/dL) of the method. It’s worth to note that 283 
the magnitude of CV of this sample could dramatically affect clinical decisions because it could 284 
potentially cause shift of the IRIS sub-stage for CKD. However, BP or P samples with low UP and 285 
UC are rare (3/120 cases in this study); therefore, the influence of high CVs at low protein 286 
concentration is negligible. The CBB method has the advantage to yield on average lower CV 287 
values compared to PRM but from a practical standpoint similar numbers of misclassifications were 288 
found in samples with UPC close to the two IRIS cut-off. Due to the magnitude of the intra-assay 289 
variability, in samples with UPC close to 0.2 and 0.4 it’s advisable to interpret results with caution 290 
and to repeat measures of UPC over time in order to properly sub-stage feline patients affected by 291 
CKD. The inter-assay CVs found in this study were higher than the most common biochemical 292 
analytes33 and could affect clinical decisions even more than intra-assay variability. However, 293 
because information about biological variability of proteinuria in cats is not available, it’s not 294 
known whether these inter-assay CV values could be considered acceptable.  295 
In this study frozen urine samples were used for the method comparison analysis. Although UC 296 
statistically increased after one month of storage at -20°C, the lack of statistical differences of UP 297 
and UPC ratio after one month of storage at -20°C suggested that measurement of proteinuria may 298 
provide reliable results in this setting and confirm that inclusion of frozen samples had no effect on 299 
method comparison study. It is important to highlight that the impact of storage on feline urinary 300 
samples was not an aim of this study. In human medicine some authors suggested to not use urine 301 
samples stored at -20°C for quantification of proteinuria, since fragmentation of proteins (mainly 302 
albumin) during storage is described.21 However, this could be a major problem using 303 
immunoassays that detect specific epitopes of albumin. Moreover, protein fragmentation in feline 304 
 13 
urine needs to be demonstrated and, whether present, it could have affected equally results of both 305 
PRM and CBB. Therefore, further evaluations are necessary to better characterize the pre-analytical 306 
variability feline urine samples due to different or longer storage conditions.  307 
Among the several commercially available automated methods for measurement of urinary 308 
proteins, the two most used dye-binding methods were evaluated in this study. Constant and 309 
proportional errors were demonstrated in the whole set of samples and agreement did not improve 310 
neither in samples with inactive sediment, where UPC values gain clinical significance.  311 
Similar results have been previously reported in a smaller group of feline samples, comparing 312 
different analytical assays (specifically, colorimetric pyrocatechol violet dye-binding says and 313 
turbidimetric benzethonium chloride assay).27 In this study, CBB yielded higher protein 314 
concentration and in turn UPC ratios when compared to PRM. Similar positive bias of CBB was 315 
demonstrated in dogs for quantification of urinary proteins26 and total protein in cerebrospinal 316 
fluid.34 Conversely, in human urine CBB tended to yield lower protein concentration when 317 
compared to PRM.24 One important cause of discrepancy between these two methods was shown to 318 
be the different responses of dyes to different types of proteins. For example, both methods were 319 
shown to constantly underestimate globulin when compared to albumin.24,35-37 Samples included in 320 
this study probably presented a large variability of protein types due to the different underlying 321 
diseases and this variability could persist also within the inactive and active sets of samples. This 322 
heterogeneity reflected the actual variability of protein patterns in samples commonly assayed in 323 
diagnostic laboratories and allowed to quantify analytical variability from a practical point of view. 324 
Analysis of the protein content of urine samples was beyond the aim of this study and whether the 325 
agreement between methods is different in specific diseases or protein patterns need further 326 
research.  327 
Because of the different response to different proteins, the use of the same standard for calibration 328 
of different methods and the use of mixed proteins instead of a single protein (such as albumin) as 329 
standard solution were proven to improve the agreement between methods.24 The two methods 330 
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evaluated in this study were calibrated with the standards provided by the manufactures. The use of 331 
the original standards had the aim to evaluate the actual variability that could be found between 332 
laboratories. Further studies are needed in order to evaluate whether the agreement between PRM 333 
and CBB improves using the same standard, possibly composed by mixed proteins or feline urinary 334 
proteins. 335 
The concordance in classifying samples according to the IRIS staging was never in the higher 336 
category of classification according to the Cohen’s k coefficients (i.e. “very good”). Although 337 
concordance in active and inactive subsets of samples was defined moderate and lower than that 338 
found in whole set of samples, k coefficients were very close in magnitude and concordance in the 339 
three sets of samples could be considered similar. It can be stated that these low concordances were 340 
the results of the tendency of CBB to misclassify samples in higher stages, as discussed above. On 341 
this regard, it’s worth to note that in some cases the magnitude of the bias was so high that samples 342 
were graded as non proteinuric with PRM and proteinuric with CBB. These patients would 343 
experience different diagnostic approaches and possibly different therapies. Taken together, the 344 
results of the method comparison study pointed out that the use of the same laboratory and the same 345 
method should be recommended in monitoring patients over time and the comparison of results 346 
between different laboratories should be avoided. Moreover, the use of external reference intervals 347 
(as determined by IRIS) could worsen the clinical effect of analytical variability. Therefore, 348 
according to these results, the use of laboratory specific reference interval, as suggested in human 349 
medicine,23 the modification of the IRIS cut-off relative to the different methods38 or alternatively 350 
the definition of one standard method by IRIS should be advocated.  351 
In conclusion, both methods were precise but samples with UPC close to the cut-off of IRIS 352 
substaging should be carefully interpreted to avoid misclassification. Intrinsic difference between 353 
analytical methods resulted in inaccuracy and suboptimal concordance in classifying samples 354 
according to IRIS substaging. This disagreement could affect clinical decisions, make questionable 355 
the comparison of UPC results between different laboratories, and have significant impact in 356 
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substaging cats affected by CKD, given the strict cut-off recommended in published guidelines in 357 
which the method of choice is not indicated. 358 
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Tables  467 
Table 1 Precision tests of protein concentration measured with PRM and CBB, creatinine concentration and UPC ratio calculated with both 468 
methods. UP, UC and UPC values are described as median and range in brackets; CV values are described as mean ± SD. 469 
 470 
 UPPRM UPCBB UC UPCPRM UPCCBB 
 
UP 
concentration 
(mg/dL)  
CV  
(%) 
UP 
concentration 
(mg/dL) 
CV 
(%) 
UC 
concentration 
(mg/dL) 
CV 
(%) 
UPC ratio 
CV 
(%) 
UPC ratio 
CV  
(%) 
Intra-assay  
all samples 
61.6 
(22.8-858.6) 
8.4 ±5.2 
87.2  
(33.4-614.8) 
5.6 ±2.6 
152.9  
(35.3-517.7) 
3.4 ±2.5 
0.32  
(0.05-24.32) 
9.5 ±4.8 
0.62  
(0.15-17.41) 
7.2 ±2.6 
Intra-assay  
active sediment 
56.5 
(22.8-455.6) 
9.3 ±6.8 
82.8  
(43.4-595.0) 
5.5 ±2.1 
152.8  
(70.0-468.5) 
3.7 ±2.8 
0.32  
(0.04-6.6) 
10.4 ±6.4 
0.61  
(0.16-7.06) 
7.1 ±2.5 
Intra-assay 
inactive sediment 
45.1 
(23,9-78.1) 
7.9 ±0.8 
57.5  
(33.4-101.7) 
7.3 ±1.4 
184.6  
(93.9-374.4)  
3.8 ±2.4  
0.19  
(0.16-0.27) 
8.2 ±1.1 
0.29  
(0.15-0.41) 
8.3 ±1.9 
Inter-assay  
all samples 
27.4  
(9.8-518.4) 
10.8 ±3.2 
51.6  
(18.2-314.6) 
10.9 ±4.5 
176.3  
(59.3-426.8) 
6.6 ±2.7 
0.15  
(0.06-6.59) 
16.4 ±9.4 
0.26  
(0.07-3.98) 
17.8 ±3.1 
  471 
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UP, urinary protein; UPPRM, urinary protein measured with pyrogallol red-molybdate; UPCBB, urinary protein measured with Coomassie brilliant 472 
blue; UC, urinary creatinine, UPC, urinary protein-to-creatinine ratio; UPCPRM urinary protein-to-creatinine ratio measured with pyrogallol red-473 
molybdate; UPCCBB urinary protein-to-creatinine ratio measured with coomassie brilliant blue 474 
475 
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 476 
Table 2 Frequency of misclassification of 4 feline urine with UPC ratios close to IRIS thresholds. When tested with PRM, 2 samples yielded UPC 477 
values close to the two IRIS cut-off (0.2 and 0.4). Similarly, two other additional samples yielded UPC values close to the same two cut-off when 478 
tested with CBB. Number (and percentage) of shifts of IRIS stage out of the 20 repeated measurements in these samples were countered. 479 
 480 
  UPC same stage UPC different stage 
UPCPRM BP (UPC =0.22) 17 (85%) 3 (15%) NP 
 P (UPC =0.42) 13 (65%) 7 (35%) BP 
UPCCBB BP (UPC =0.22) 18 (90%) 2 (10%) NP 
 P (UPC =0.41) 11 (55%) 9 (45%) BP 
UPC, urinary protein-to-creatinine ratio; UPCPRM urinary protein-to-creatinine ratio measured with pyrogallol red-molybdate; UPCCBB urinary 481 
protein-to-creatinine ratio measured with coomassie brilliant blue; BP, borderline proteinuric; P, proteinuric 482 
483 
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 484 
Table 3: Median (range) of UP, UC and UPC of the 120 samples included in the method comparison. Data of the whole caseload and of samples 485 
with inactive or active sediment are shown.  486 
 487 
 All samples Active sediment Inactive sediment 
UPPRM (mg/dL) 28.9 (0.9-919.7) 40.3 (2.3-919.7)a 25.5 (0.9-345.3) 
UPCBB (mg/dL) 56.6 (2.8-614.8) 74.2 (8.9-595.0)a 48.2 (2.8-286.3)  
UC (mg/dL) 162.0 (23.9-234.2) 152.9 (23.9-632.6) 158.2 (28.2-520.7) 
UPCPRM 0.17 (0.01-24.32) 0.28 (0.02-12.92)b 0.15 (0.01-6.97) 
UPCCBB 0.31 (0.03-17.41) 0.42 (0.09-14.95)c 0.22 (0.03-5.78) 
UPPRM, urinary protein measured with pyrogallol red-molybdate; UPCBB, urinary protein measured with Coomassie brilliant blue; UC, urinary 488 
creatinine; UPCPRM urinary protein-to-creatinine ratio measured with pyrogallol red-molybdate; UPCCBB urinary protein-to-creatinine ratio 489 
measured with coomassie brilliant blue. 490 
Letters indicate which P value refer to comparison between samples with active vs inactive sediment: a <0.05, b P <0.005, c P <0.01 491 
492 
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 493 
Table 4 Intercept and slope of Passing-Bablok tests and bias and P values recorded in Bland–Altman tests (showed in Figure 2 and 3) of UP and 494 
UPC ratios measured with both methods for the whole set of sample and for active and inactive sets of samples. Cohen’s k coefficients describing 495 
the concordance in classify samples according to International Renal Interest Society (IRIS) are also showed. 496 
 497 
  Passing-Bablok Bland-Altman Cohen 
  Intercept (95% CI) Slope (95% CI) Bias (95% CI)  K coefficients 
All UP 
10.70  
(6.67 to 14.91) 
1.21  
(1.10 to 1.33) 
-17,82  
(-7.50 to -28.14) 
 
 UPC  
0.03  
(0.02 to 0.05) 
1.27  
(1.18 to 1.43) 
-0.11  
(0.02 to -0.25) 
0.62 
Active UP 
13.01 
(5.27 to 20.77) 
1.14  
(1.01 to 1.27) 
-19.61  
(4.72 to -43.95) 
 
 UPC 
0.07  
(0.03 to 0.10) 
1.15  
(1.04 to 1.30) 
-0.2  
(-0.06 to -0.34) 
0.59 
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 498 
UP, urinary protein; UPC, urinary protein-to-creatinine ratio 499 
Inactive UP 
7.6  
(0.39 to 15.44) 
1.29  
(1.05 to 1.61) 
-17.68  
(-12.6 to -22.77) 
 
 UPC 
0.01 
(-0.02 to 0.04) 
1.49 
(1.26 to 1.83) 
-0.14  
(-0.05 to -0.23) 
0.56 
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Figure captions 1 
Figure 1 Passing-Bablok plot showing the comparison of urinary protein (UP) between Pyrogallol 2 
red-molybdate (PRM) and Coomassie brilliant blue (CBB) obtained from 120 cats in whole set of 3 
sample (A) and for active (B) and inactive (C) sets of samples. The blue line is the correlation, the 4 
gray line shows best fit and the blue dotted lines represent 95% CI. 5 
 6 
Figure 2 Passing-Bablok plot showing the comparison of urinary protein-to-creatinine (UPC) ratio 7 
between Pyrogallol red-molybdate (PRM) and Coomassie brilliant blue (CBB) obtained from 120 8 
cats in whole set of sample (A) and for active (B) and inactive (C) sets of samples. The blue line is 9 
the correlation, the gray line shows best fit and the blue dotted lines represent 95% CI. 10 
 11 
Figure 3 Bland-Altman plot showing the comparison of urinary protein (UP) between Pyrogallol 12 
red-molybdate (PRM) and Coomassie brilliant blue (CBB) obtained from 120 cats in whole set (A) 13 
of sample and for active (B) and inactive (C) sets of samples. X axes represent the average between 14 
the two methods, and the Y axes the indicate the difference between PRM and CBB; the grey line 15 
shows the zero bias, the blue solid with the dashed blue lines represent the bias and 95% confidence 16 
interval (CI), respectively, the light blue dashed lines are the limits of agreement and the red dotted 17 
line is the regression line.  18 
 19 
Figure 4 Bland-Altman plot showing the comparison of urinary protein-to-creatine (UPC) ratio 20 
between Pyrogallol red-molybdate (PRM) and Coomassie brilliant blue (CBB) obtained from 120 21 
cats in whole set (A) of sample and for active (B) and inactive (C) sets of samples. X axes represent 22 
the average between the two methods, and the Y axes the indicate the difference between PRM and 23 
CBB; the grey line shows the zero bias, the blue solid with the dashed blue lines represent the bias 24 
and 95% confidence interval (CI), respectively, the light blue dashed lines are the limits of 25 
agreement and the red dotted line is the regression line.  26 
